PHAM QUANG X (CEO and Chairman) sold 1.2% of their position (2.44K shares) of CADRENAL THERAPEUTICS, INC. on the open market
Open‑market sale worth $34.2K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 10/28/2025ACC: 0001213900-25-103146
DirectorOfficer10% Owner· CEO and Chairman
Since Jan 2023
-2.44K
Net shares
Net seller
$34.2K
Total sold
2
Open market trades
0B · 2S
2
Total transactions
2.44K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
−1.13K
Price / share
$14.03
Trade value
$15.84K
% of position
0.6%
10/24/2025
198.53K→197.40K
Common Stock
Direct
Shares
−1.31K
Price / share
$13.99
Trade value
$18.40K
% of position
0.7%
10/27/2025
197.40K→196.09K
Total
Net shares
−2.44K
Net value
-$34.24K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 10/24/2025 | S · Sale | −1.13K | $14.03 | $15.84K | 0.6% | 198.53K | 197.40K |
| Common Stock Direct | 10/27/2025 | S · Sale | −1.31K | $13.99 | $18.40K | 0.7% | 197.40K | 196.09K |
| Total | −2.44K | -$34.24K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned200K
Total
200K indirect200K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 200K | Indirect |
| Total | 200K | 200K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported